Novel drug-eluting stents in the treatment of de novo coronary lesions
Davide Capodanno1,2, Fabio Dipasqua1, Corrado Tamburino1,2
1Department of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy; 2ETNA Foundation, Catania, Italy
Abstract: Due to safety concerns in recent years, much effort has been devoted to improving the outcomes associated with drug-eluting stents (DESs). This review summarizes the current status of methodological and technical achievements reported in second-generation DES. Novel stents are described based on the component (the platform, the polymer, and the drug) that has undergone the most significant changes compared to earlier generation DES. An overview of the currently available evidence on the use of novel coronary devices in patients undergoing coronary revascularization is also reviewed.
Keywords: coronary artery disease, stent, platform, polymer, drug, percutaneous coronary intervention, late lumen loss, follow-up, outcomes
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.